
CLAIMS

What is claimed is:

1. Use of a pharmaceutical composition comprising a therapeutically effective amount of compound (1)



(1)

or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of cancer in a subject in need thereof, wherein the cancer is a midline glioma and has a histone H3 K27M mutation, and wherein the medicament is to be administered to the subject at a predetermined dose with a frequency selected from one or more of:

a) once daily;
b) according to a frequent dosing regimen, wherein the medicament is to be administered more than once per week;
c) once weekly;
d) once every four weeks;
e) twice a week;
f) once every two weeks; and
g) in a repeated cycle of once weekly, once every two weeks, once every three weeks, once every four weeks or combinations thereof.

2. The use according to claim 1, wherein the cancer involves the thalamus, medulla, hypothalamus, basal ganglia, pineal gland, midbrain, cerebellum, pons, or spinal cord.

3. The use according to claim 1 or 2, wherein the histone H3 K27M mutation is H3.3 K27M or H3.1 K27M.

4. The use according to any one of claims 1 to 3, wherein the histone H3 K27M mutation is in one or more histone genes selected from *H3F3A, H3F3B, HIST1H3A, HIST1H3B, HIST1H3C, HIST1H3D, HIST1H3E, HIST1H3F, HIST1H3G, HIST1H3H, HIST1H3I, or HIST1H3 J.*

5. The use according to any one of claims 1 to 4, wherein in cancerous tissue DRD2 is overexpressed, DRD5 is underexpressed, or both.

6. The use according to any one of claims 1 to 5, wherein the subject is a human.

7. The use according to any one of claims 1 to 5, wherein the subject is a domesticated pet.

8. The use according to claim 6, wherein the subject is a pediatric subject.

9. The use according to any one of claims 1 to 8, wherein the pharmaceutically acceptable salt is a dihydrochloride salt.

10. The use according to any of claims 1 to 9, wherein the predetermined dose is 625 mg.

11. The use according to any of claims 1 to 10, wherein the medicament is to be administered with one or more radiation treatment.

12. The use according to claim 11, wherein the radiation treatment is to be administered concurrently or sequentially in any order.

13. The use according to any of claims 1 to 12, wherein the predetermined dose is 5 to 10 mg/kg.

14. The use according to any of claims 1 to 13, wherein the predetermined dose is 37.5 to 1500 mg/m^2.